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background:  The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial was a prospective, randomized, open-label, 
blinded-endpoint design with three T/L-type dihydropyridine calcium channel blocker benidipine-based regimens: angiotensin receptor blocker 
(ARB), β-blocker, or thiazide, in hypertensive outpatients between the ages of 40 and 85 years who did not achieve the target blood pressure 
(<140/90 mm Hg) with 4 mg per day of benidipine. A total of 3293 patients (ARB; 1110, β-blocker; 1089, and thiazide; 1094, respectively) who 
received each combination treatment were included in the analysis. Median follow-up was 3.61 years. The results of the COPE trial demonstrated 
that the incidence of hard cardiovascular composite endpoints and the incidence of fatal or non-fatal strokes were higher in the benidipine-β-
blocker group than in the benidipine-thiazide group (P = 0.0201, P = 0.0109, respectively).
methods:  In this pre-specified sub-analysis, we further evaluated the treatment effects on different cardiac events among the three benidipine-
based regimens.
results:  We observed a total of 50 cardiac events, 4.2 per 1000 person-years; fatal or non-fatal myocardial infarctions: 12, 1.0 per 1000 
person-years; sudden cardiac deaths: 2, 0.2 per 1000 person-years; hospitalizations due to unstable angina: 27, 2.3 per 1000 person-years; 
and hospitalizations due to new onset of heart failure (New York Heart Association class II-IV): 10, 0.8 per 1000 person-years, respectively. Few 
differences in each cardiac event were observed among the three treatment groups (fatal or non-fatal myocardial infarction, P = 0.808; sudden 
cardiac death, P = 0.606; hospitalization due to unstable angina, P = 0.669; and hospitalization due to new onset of heart failure, P = 0.884) and 
multi-adjusted hazard ratios of the incidence of all cardiac events were not different among the three treatment groups.
conclusions:  This pre-specified sub-analysis of the COPE trial demonstrated that blood pressure-lowering therapy with benidipine combined with 
ARB, β-blocker, or thiazide diuretic was similarly effective in the prevention of cardiac events in hypertensive outpatients.
